Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 70.25

+0.1%

Nov 6 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2021)	11/6/2007 12:13:27 PM
From: Jibacoa	Read Replies (1) of 3722

SNTS seems to have found support at the $2 level since it dropped from the $5.25 level in August. bigcharts.marketwatch.com SNTS has been trimming its loss for 4 consecutive Qs & revenues have significantly increased (in triple digit improvements) also for 4Qs. Zegerid prescriptions reportedly grew approximately 12% in the 3rdQ compared with the 2ndQ, while the delayed released brands, Nexium, Prevacid, Protonix, and Aciphex, as a group had negative growth of more than 2%.For the 9Ms ended September 30, prescription for Zegerid grew approximately 143% in contrast to 2% negative growth for prescriptions for the delayed release brand. In August was when Par alleged that U.S. Patents for ZEGERID are invalid, unenforceable and/or will not be infringed by Par's manufacture, use, or sale of the product for which it had submitted an ANDA.<g> At any rate, SNTS shares are up > 7% today & it seems they could get back to the $4 level some time in the near future.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next